Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology Vol. 19; no. 5; pp. 705 - 714
Main Authors: Laetsch, Theodore W, DuBois, Steven G, Mascarenhas, Leo, Turpin, Brian, Federman, Noah, Albert, Catherine M, Nagasubramanian, Ramamoorthy, Davis, Jessica L, Rudzinski, Erin, Feraco, Angela M, Tuch, Brian B, Ebata, Kevin T, Reynolds, Mark, Smith, Steven, Cruickshank, Scott, Cox, Michael C, Pappo, Alberto S, Hawkins, Douglas S
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01.05.2018
Elsevier Limited
Subjects:
Administration, Oral
Adolescent
Adolescents
Age
Age Factors
Alanine
Alanine transaminase
Anthracycline
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Aspartate aminotransferase
Biomarkers, Tumor - antagonists & inhibitors
Biomarkers, Tumor - genetics
Cancer therapies
Central nervous system
Chemotherapy
Child
Child, Preschool
Children
Clinical trials
Discoidin Domain Receptor 2 - antagonists & inhibitors
Discoidin Domain Receptor 2 - genetics
Drug Administration Schedule
Female
Fibrosarcoma
Gene Fusion
Humans
Infant
Infants
Kinases
Leukopenia
Male
Membrane Glycoproteins - antagonists & inhibitors
Membrane Glycoproteins - genetics
Metastases
Metastasis
Nausea
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - pathology
Neuroblastoma
Neutrophils
Oncology
Papillary thyroid cancer
Patients
Pediatrics
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Pyrazoles - administration & dosage
Pyrazoles - adverse effects
Pyrimidines - administration & dosage
Pyrimidines - adverse effects
Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
Receptor Protein-Tyrosine Kinases - genetics
Receptor, trkA - antagonists & inhibitors
Receptor, trkA - genetics
Receptor, trkB - antagonists & inhibitors
Receptor, trkB - genetics
Safety
Solid tumors
Surgery
Thyroid cancer
Time Factors
Toxicity
Treatment Outcome
Tumors
United States
Vomiting
Young Adult
United States
ISSN:1470-2045, 1474-5488, 1474-5488
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients. This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy. Following a protocol amendment on Sept 12, 2016, patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery to achieve a complete surgical resection were also eligible. Patients were enrolled to three dose cohorts according to a rolling six design. Larotrectinib was administered orally (capsule or liquid formulation), twice daily, on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. The primary endpoint of the phase 1 dose escalation component was the safety of larotrectinib, including dose-limiting toxicity. All patients who received at least one dose of larotrectinib were included in the safety analyses. Reported here are results of the phase 1 dose escalation cohort. Phase 1 follow-up and phase 2 are ongoing. This trial is registered with ClinicalTrials.gov, number NCT02637687. Between Dec 21, 2015, and April 13, 2017, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) with a median age of 4·5 years (IQR 1·3–13·3) were enrolled to three dose cohorts: cohorts 1 and 2 were assigned doses on the basis of both age and bodyweight predicted by use of SimCyp modelling to achieve an area under the curve equivalent to the adult doses of 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2); and cohort 3 was assigned to receive a dose of 100 mg/m2 twice daily (maximum 100 mg per dose), regardless of age, equating to a maximum of 173% of the recommended adult phase 2 dose. Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. Adverse events were predominantly grade 1 or 2 (occurring in 21 [88%] of 24 patients); the most common larotrectinib-related adverse events of all grades were increased alanine and aspartate aminotransferase (ten [42%] of 24 each), leucopenia (five [21%] of 24), decreased neutrophil count (five [21%] of 24), and vomiting (five [21%] of 24). Grade 3 alanine aminotransferase elevation was the only dose-limiting toxicity and occurred in one patient without a TRK fusion and with progressive disease. No grade 4 or 5 treatment-related adverse events were observed. Two larotrectinib-related serious adverse events were observed: grade 3 nausea and grade 3 ejection fraction decrease during the 28-day follow-up after discontinuing larotrectinib and while on anthracyclines. The maximum tolerated dose was not reached, and 100 mg/m2 (maximum of 100 mg per dose) was established as the recommended phase 2 dose. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response. The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours. The recommended phase 2 dose was defined as 100mg/m2 (maximum 100 mg per dose) for infants, children, and adolescents, regardless of age. Loxo Oncology Inc.
AbstractList Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients.BACKGROUNDGene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients.This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy. Following a protocol amendment on Sept 12, 2016, patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery to achieve a complete surgical resection were also eligible. Patients were enrolled to three dose cohorts according to a rolling six design. Larotrectinib was administered orally (capsule or liquid formulation), twice daily, on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. The primary endpoint of the phase 1 dose escalation component was the safety of larotrectinib, including dose-limiting toxicity. All patients who received at least one dose of larotrectinib were included in the safety analyses. Reported here are results of the phase 1 dose escalation cohort. Phase 1 follow-up and phase 2 are ongoing. This trial is registered with ClinicalTrials.gov, number NCT02637687.METHODSThis multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy. Following a protocol amendment on Sept 12, 2016, patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery to achieve a complete surgical resection were also eligible. Patients were enrolled to three dose cohorts according to a rolling six design. Larotrectinib was administered orally (capsule or liquid formulation), twice daily, on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. The primary endpoint of the phase 1 dose escalation component was the safety of larotrectinib, including dose-limiting toxicity. All patients who received at least one dose of larotrectinib were included in the safety analyses. Reported here are results of the phase 1 dose escalation cohort. Phase 1 follow-up and phase 2 are ongoing. This trial is registered with ClinicalTrials.gov, number NCT02637687.Between Dec 21, 2015, and April 13, 2017, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) with a median age of 4·5 years (IQR 1·3-13·3) were enrolled to three dose cohorts: cohorts 1 and 2 were assigned doses on the basis of both age and bodyweight predicted by use of SimCyp modelling to achieve an area under the curve equivalent to the adult doses of 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2); and cohort 3 was assigned to receive a dose of 100 mg/m2 twice daily (maximum 100 mg per dose), regardless of age, equating to a maximum of 173% of the recommended adult phase 2 dose. Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. Adverse events were predominantly grade 1 or 2 (occurring in 21 [88%] of 24 patients); the most common larotrectinib-related adverse events of all grades were increased alanine and aspartate aminotransferase (ten [42%] of 24 each), leucopenia (five [21%] of 24), decreased neutrophil count (five [21%] of 24), and vomiting (five [21%] of 24). Grade 3 alanine aminotransferase elevation was the only dose-limiting toxicity and occurred in one patient without a TRK fusion and with progressive disease. No grade 4 or 5 treatment-related adverse events were observed. Two larotrectinib-related serious adverse events were observed: grade 3 nausea and grade 3 ejection fraction decrease during the 28-day follow-up after discontinuing larotrectinib and while on anthracyclines. The maximum tolerated dose was not reached, and 100 mg/m2 (maximum of 100 mg per dose) was established as the recommended phase 2 dose. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.FINDINGSBetween Dec 21, 2015, and April 13, 2017, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) with a median age of 4·5 years (IQR 1·3-13·3) were enrolled to three dose cohorts: cohorts 1 and 2 were assigned doses on the basis of both age and bodyweight predicted by use of SimCyp modelling to achieve an area under the curve equivalent to the adult doses of 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2); and cohort 3 was assigned to receive a dose of 100 mg/m2 twice daily (maximum 100 mg per dose), regardless of age, equating to a maximum of 173% of the recommended adult phase 2 dose. Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. Adverse events were predominantly grade 1 or 2 (occurring in 21 [88%] of 24 patients); the most common larotrectinib-related adverse events of all grades were increased alanine and aspartate aminotransferase (ten [42%] of 24 each), leucopenia (five [21%] of 24), decreased neutrophil count (five [21%] of 24), and vomiting (five [21%] of 24). Grade 3 alanine aminotransferase elevation was the only dose-limiting toxicity and occurred in one patient without a TRK fusion and with progressive disease. No grade 4 or 5 treatment-related adverse events were observed. Two larotrectinib-related serious adverse events were observed: grade 3 nausea and grade 3 ejection fraction decrease during the 28-day follow-up after discontinuing larotrectinib and while on anthracyclines. The maximum tolerated dose was not reached, and 100 mg/m2 (maximum of 100 mg per dose) was established as the recommended phase 2 dose. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours. The recommended phase 2 dose was defined as 100mg/m2 (maximum 100 mg per dose) for infants, children, and adolescents, regardless of age.INTERPRETATIONThe TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours. The recommended phase 2 dose was defined as 100mg/m2 (maximum 100 mg per dose) for infants, children, and adolescents, regardless of age.Loxo Oncology Inc.FUNDINGLoxo Oncology Inc.
Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients. This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy. Following a protocol amendment on Sept 12, 2016, patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery to achieve a complete surgical resection were also eligible. Patients were enrolled to three dose cohorts according to a rolling six design. Larotrectinib was administered orally (capsule or liquid formulation), twice daily, on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. The primary endpoint of the phase 1 dose escalation component was the safety of larotrectinib, including dose-limiting toxicity. All patients who received at least one dose of larotrectinib were included in the safety analyses. Reported here are results of the phase 1 dose escalation cohort. Phase 1 follow-up and phase 2 are ongoing. This trial is registered with ClinicalTrials.gov, number NCT02637687. Between Dec 21, 2015, and April 13, 2017, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) with a median age of 4·5 years (IQR 1·3-13·3) were enrolled to three dose cohorts: cohorts 1 and 2 were assigned doses on the basis of both age and bodyweight predicted by use of SimCyp modelling to achieve an area under the curve equivalent to the adult doses of 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2); and cohort 3 was assigned to receive a dose of 100 mg/m twice daily (maximum 100 mg per dose), regardless of age, equating to a maximum of 173% of the recommended adult phase 2 dose. Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. Adverse events were predominantly grade 1 or 2 (occurring in 21 [88%] of 24 patients); the most common larotrectinib-related adverse events of all grades were increased alanine and aspartate aminotransferase (ten [42%] of 24 each), leucopenia (five [21%] of 24), decreased neutrophil count (five [21%] of 24), and vomiting (five [21%] of 24). Grade 3 alanine aminotransferase elevation was the only dose-limiting toxicity and occurred in one patient without a TRK fusion and with progressive disease. No grade 4 or 5 treatment-related adverse events were observed. Two larotrectinib-related serious adverse events were observed: grade 3 nausea and grade 3 ejection fraction decrease during the 28-day follow-up after discontinuing larotrectinib and while on anthracyclines. The maximum tolerated dose was not reached, and 100 mg/m (maximum of 100 mg per dose) was established as the recommended phase 2 dose. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response. The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours. The recommended phase 2 dose was defined as 100mg/m (maximum 100 mg per dose) for infants, children, and adolescents, regardless of age. Loxo Oncology Inc.
Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients. This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy. Following a protocol amendment on Sept 12, 2016, patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery to achieve a complete surgical resection were also eligible. Patients were enrolled to three dose cohorts according to a rolling six design. Larotrectinib was administered orally (capsule or liquid formulation), twice daily, on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. The primary endpoint of the phase 1 dose escalation component was the safety of larotrectinib, including dose-limiting toxicity. All patients who received at least one dose of larotrectinib were included in the safety analyses. Reported here are results of the phase 1 dose escalation cohort. Phase 1 follow-up and phase 2 are ongoing. This trial is registered with ClinicalTrials.gov, number NCT02637687. Between Dec 21, 2015, and April 13, 2017, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) with a median age of 4·5 years (IQR 1·3–13·3) were enrolled to three dose cohorts: cohorts 1 and 2 were assigned doses on the basis of both age and bodyweight predicted by use of SimCyp modelling to achieve an area under the curve equivalent to the adult doses of 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2); and cohort 3 was assigned to receive a dose of 100 mg/m2 twice daily (maximum 100 mg per dose), regardless of age, equating to a maximum of 173% of the recommended adult phase 2 dose. Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. Adverse events were predominantly grade 1 or 2 (occurring in 21 [88%] of 24 patients); the most common larotrectinib-related adverse events of all grades were increased alanine and aspartate aminotransferase (ten [42%] of 24 each), leucopenia (five [21%] of 24), decreased neutrophil count (five [21%] of 24), and vomiting (five [21%] of 24). Grade 3 alanine aminotransferase elevation was the only dose-limiting toxicity and occurred in one patient without a TRK fusion and with progressive disease. No grade 4 or 5 treatment-related adverse events were observed. Two larotrectinib-related serious adverse events were observed: grade 3 nausea and grade 3 ejection fraction decrease during the 28-day follow-up after discontinuing larotrectinib and while on anthracyclines. The maximum tolerated dose was not reached, and 100 mg/m2 (maximum of 100 mg per dose) was established as the recommended phase 2 dose. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response. The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours. The recommended phase 2 dose was defined as 100mg/m2 (maximum 100 mg per dose) for infants, children, and adolescents, regardless of age. Loxo Oncology Inc.
Summary Background Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients. Methods This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy. Following a protocol amendment on Sept 12, 2016, patients with locally advanced infantile fibrosarcoma who would require disfiguring surgery to achieve a complete surgical resection were also eligible. Patients were enrolled to three dose cohorts according to a rolling six design. Larotrectinib was administered orally (capsule or liquid formulation), twice daily, on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. The primary endpoint of the phase 1 dose escalation component was the safety of larotrectinib, including dose-limiting toxicity. All patients who received at least one dose of larotrectinib were included in the safety analyses. Reported here are results of the phase 1 dose escalation cohort. Phase 1 follow-up and phase 2 are ongoing. This trial is registered with ClinicalTrials.gov, number NCT02637687. Findings Between Dec 21, 2015, and April 13, 2017, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) with a median age of 4·5 years (IQR 1·3–13·3) were enrolled to three dose cohorts: cohorts 1 and 2 were assigned doses on the basis of both age and bodyweight predicted by use of SimCyp modelling to achieve an area under the curve equivalent to the adult doses of 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2); and cohort 3 was assigned to receive a dose of 100 mg/m2 twice daily (maximum 100 mg per dose), regardless of age, equating to a maximum of 173% of the recommended adult phase 2 dose. Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. Adverse events were predominantly grade 1 or 2 (occurring in 21 [88%] of 24 patients); the most common larotrectinib-related adverse events of all grades were increased alanine and aspartate aminotransferase (ten [42%] of 24 each), leucopenia (five [21%] of 24), decreased neutrophil count (five [21%] of 24), and vomiting (five [21%] of 24). Grade 3 alanine aminotransferase elevation was the only dose-limiting toxicity and occurred in one patient without a TRK fusion and with progressive disease. No grade 4 or 5 treatment-related adverse events were observed. Two larotrectinib-related serious adverse events were observed: grade 3 nausea and grade 3 ejection fraction decrease during the 28-day follow-up after discontinuing larotrectinib and while on anthracyclines. The maximum tolerated dose was not reached, and 100 mg/m2 (maximum of 100 mg per dose) was established as the recommended phase 2 dose. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response as per Response Evaluation Criteria In Solid Tumors version 1.1; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response. Interpretation The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours. The recommended phase 2 dose was defined as 100mg/m2 (maximum 100 mg per dose) for infants, children, and adolescents, regardless of age. Funding Loxo Oncology Inc.
Author Davis, Jessica L
Rudzinski, Erin
Ebata, Kevin T
Cruickshank, Scott
Mascarenhas, Leo
Federman, Noah
Pappo, Alberto S
Turpin, Brian
Nagasubramanian, Ramamoorthy
Laetsch, Theodore W
DuBois, Steven G
Reynolds, Mark
Tuch, Brian B
Cox, Michael C
Smith, Steven
Hawkins, Douglas S
Albert, Catherine M
Feraco, Angela M
Author_xml – sequence: 1
  givenname: Theodore W
  surname: Laetsch
  fullname: Laetsch, Theodore W
  email: ted.laetsch@utsouthwestern.edu
  organization: University of Texas Southwestern Medical Center/Children's Health, Dallas, TX, USA
– sequence: 2
  givenname: Steven G
  surname: DuBois
  fullname: DuBois, Steven G
  organization: Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA
– sequence: 3
  givenname: Leo
  surname: Mascarenhas
  fullname: Mascarenhas, Leo
  organization: Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
– sequence: 4
  givenname: Brian
  surname: Turpin
  fullname: Turpin, Brian
  organization: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
– sequence: 5
  givenname: Noah
  surname: Federman
  fullname: Federman, Noah
  organization: University of California, Los Angeles, Los Angeles, CA, USA
– sequence: 6
  givenname: Catherine M
  surname: Albert
  fullname: Albert, Catherine M
  organization: Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center Seattle, WA, USA
– sequence: 7
  givenname: Ramamoorthy
  surname: Nagasubramanian
  fullname: Nagasubramanian, Ramamoorthy
  organization: Nemours Children's Hospital, Orlando, FL, USA
– sequence: 8
  givenname: Jessica L
  surname: Davis
  fullname: Davis, Jessica L
  organization: Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center Seattle, WA, USA
– sequence: 9
  givenname: Erin
  surname: Rudzinski
  fullname: Rudzinski, Erin
  organization: Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center Seattle, WA, USA
– sequence: 10
  givenname: Angela M
  surname: Feraco
  fullname: Feraco, Angela M
  organization: Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA
– sequence: 11
  givenname: Brian B
  surname: Tuch
  fullname: Tuch, Brian B
  organization: Loxo Oncology Inc, South San Francisco, CA, USA
– sequence: 12
  givenname: Kevin T
  surname: Ebata
  fullname: Ebata, Kevin T
  organization: Loxo Oncology Inc, South San Francisco, CA, USA
– sequence: 13
  givenname: Mark
  surname: Reynolds
  fullname: Reynolds, Mark
  organization: Loxo Oncology Inc, South San Francisco, CA, USA
– sequence: 14
  givenname: Steven
  surname: Smith
  fullname: Smith, Steven
  organization: Loxo Oncology Inc, South San Francisco, CA, USA
– sequence: 15
  givenname: Scott
  surname: Cruickshank
  fullname: Cruickshank, Scott
  organization: Loxo Oncology Inc, South San Francisco, CA, USA
– sequence: 16
  givenname: Michael C
  surname: Cox
  fullname: Cox, Michael C
  organization: Loxo Oncology Inc, South San Francisco, CA, USA
– sequence: 17
  givenname: Alberto S
  surname: Pappo
  fullname: Pappo, Alberto S
  organization: St Jude Children's Research Hospital, Memphis, TN, USA
– sequence: 18
  givenname: Douglas S
  surname: Hawkins
  fullname: Hawkins, Douglas S
  organization: Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center Seattle, WA, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29606586$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1vFCEUhiemxn7oT9CQeNMmHQszsAM1xpjGr7jRROs1AeZMS2VgBKbJ_gN_tuxu68Xe1CsO5HnPgfflsNrzwUNVPSf4FcFkcfaD0A7XDabsmPCTFhMiavyoOijHtGaU871NvUX2q8OUbjAmHcHsSbXfiAVeML44qP4sVQw5gsnWW42GENGkoLcqR2tQCs72KM9jmGNC1yrqUlh_hb5efv-CrsADGuZkg0_naLpWCRBBEdLsckJDDCNSaCwba8CXGacoTOBrpzS403v-rEEpz_3qafV4UC7Bs7v1qPr54f3lxad6-e3j54t3y9pQQXPNsOJM6xYUMAFCGNDN0Cgu9IIO3GhKW83I0HdGdZpTo0HoQbRdR_uGr6uj6njbd4rh9wwpy9EmA84pD2FOssEN5oIw2hb05Q56U57vy-0K1eKuuMi7Qr24o2Y9Qi-naEcVV_Le4wKwLWBiSCnC8A8hWK6zlJss5TooSbjcZClx0b3e0RmbVS5u56ise1D9dquGYuathSiTseBNyXadtuyDfbDDm50OxpVPYpT7Bav_0P8FUPbMBA
CitedBy_id crossref_primary_10_1007_s40265_022_01820_1
crossref_primary_10_3389_fendo_2021_748941
crossref_primary_10_1038_s41467_022_28661_6
crossref_primary_10_1016_j_annonc_2023_08_015
crossref_primary_10_3389_fonc_2025_1504803
crossref_primary_10_1002_cpt_1946
crossref_primary_10_1002_ccr3_3804
crossref_primary_10_1002_pbc_30679
crossref_primary_10_1158_2159_8290_CD_21_0094
crossref_primary_10_3389_fonc_2024_1332522
crossref_primary_10_1080_14656566_2021_1876664
crossref_primary_10_1038_s41416_018_0251_2
crossref_primary_10_3389_fonc_2023_1204829
crossref_primary_10_3390_cancers13112539
crossref_primary_10_1097_PAS_0000000000001203
crossref_primary_10_17163_lgr_n42_2025_07
crossref_primary_10_1002_mco2_105
crossref_primary_10_1016_j_path_2021_03_002
crossref_primary_10_1182_blood_2018_06_857540
crossref_primary_10_1080_14740338_2023_2274426
crossref_primary_10_1007_s12094_021_02558_0
crossref_primary_10_1200_JCO_25_00009
crossref_primary_10_3390_biomedicines13082038
crossref_primary_10_1016_j_ctrv_2021_102259
crossref_primary_10_1016_j_ejca_2019_03_019
crossref_primary_10_1016_j_critrevonc_2021_103451
crossref_primary_10_1016_j_hoc_2025_04_004
crossref_primary_10_1016_j_soc_2022_03_003
crossref_primary_10_1007_s00401_022_02405_8
crossref_primary_10_1002_gcc_23205
crossref_primary_10_1007_s12105_019_01104_3
crossref_primary_10_12688_f1000research_16236_1
crossref_primary_10_1093_annonc_mdz282
crossref_primary_10_1002_ijc_33690
crossref_primary_10_1038_s41573_025_01147_y
crossref_primary_10_1002_path_6260
crossref_primary_10_1016_j_ejmech_2024_117231
crossref_primary_10_1097_PAS_0000000000001437
crossref_primary_10_1210_endrev_bnaf003
crossref_primary_10_3390_cancers14205022
crossref_primary_10_1016_j_ejca_2025_115627
crossref_primary_10_1016_j_annonc_2020_11_021
crossref_primary_10_1093_oncolo_oyac080
crossref_primary_10_3390_ijms24076026
crossref_primary_10_3390_ijms25136961
crossref_primary_10_1007_s00761_019_0552_y
crossref_primary_10_1038_s41379_020_00657_x
crossref_primary_10_1002_jcph_1377
crossref_primary_10_1038_s41591_019_0542_z
crossref_primary_10_1002_gcc_22681
crossref_primary_10_5306_wjco_v12_i4_217
crossref_primary_10_1093_jnen_nlab016
crossref_primary_10_1111_his_14847
crossref_primary_10_1200_JCO_24_00848
crossref_primary_10_3390_ijms21030753
crossref_primary_10_1007_s00431_024_05540_4
crossref_primary_10_1097_MPH_0000000000002871
crossref_primary_10_3390_diagnostics11030478
crossref_primary_10_1002_cncr_31701
crossref_primary_10_1111_ajco_13727
crossref_primary_10_1080_17512433_2019_1661775
crossref_primary_10_1111_cts_13547
crossref_primary_10_1124_pr_118_016972
crossref_primary_10_1016_j_jval_2021_11_1354
crossref_primary_10_1016_S1470_2045_19_30856_3
crossref_primary_10_1038_s41379_021_00806_w
crossref_primary_10_20344_amp_21925
crossref_primary_10_1016_j_jmoldx_2020_11_005
crossref_primary_10_1007_s10555_020_09850_5
crossref_primary_10_3390_cancers15010105
crossref_primary_10_1016_j_ejca_2020_06_028
crossref_primary_10_1007_s40272_020_00380_9
crossref_primary_10_3389_fphar_2021_747895
crossref_primary_10_1002_pbc_31734
crossref_primary_10_1016_j_jtho_2019_07_022
crossref_primary_10_1080_14712598_2024_2408754
crossref_primary_10_1080_14737140_2023_2236305
crossref_primary_10_1016_j_ejmech_2019_06_064
crossref_primary_10_1016_j_yamp_2018_07_008
crossref_primary_10_1016_S1470_2045_20_30023_1
crossref_primary_10_1093_annonc_mdz382
crossref_primary_10_1111_his_14069
crossref_primary_10_1016_j_apsb_2020_05_004
crossref_primary_10_1016_j_gore_2019_04_006
crossref_primary_10_1055_a_2072_9505
crossref_primary_10_1002_pbc_28330
crossref_primary_10_1007_s15015_020_2350_1
crossref_primary_10_3389_fonc_2023_1252359
crossref_primary_10_1111_cas_15465
crossref_primary_10_1002_pbc_28694
crossref_primary_10_1200_JCO_18_00573
crossref_primary_10_3389_fonc_2021_679701
crossref_primary_10_3389_fonc_2022_1037531
crossref_primary_10_1177_0883073820931635
crossref_primary_10_1002_gcc_22700
crossref_primary_10_1200_EDBK_278893
crossref_primary_10_1038_s41467_019_12187_5
crossref_primary_10_1111_cup_14216
crossref_primary_10_1530_EJE_21_1259
crossref_primary_10_1080_17460441_2020_1767064
crossref_primary_10_3390_cancers15061766
crossref_primary_10_1016_j_ejca_2025_115600
crossref_primary_10_2217_pgs_2019_0064
crossref_primary_10_1002_gcc_22949
crossref_primary_10_1016_j_semcancer_2021_06_008
crossref_primary_10_1002_gcc_23111
crossref_primary_10_1080_13543784_2021_1896703
crossref_primary_10_1038_s41379_020_00693_7
crossref_primary_10_1242_dmm_048930
crossref_primary_10_1016_j_drudis_2024_104031
crossref_primary_10_3389_fendo_2023_1176731
crossref_primary_10_1016_S1470_2045_20_30074_7
crossref_primary_10_1097_CCO_0000000000000650
crossref_primary_10_1177_1078155220938849
crossref_primary_10_1016_S1470_2045_18_30191_8
crossref_primary_10_1007_s00761_021_01084_6
crossref_primary_10_1016_j_currproblcancer_2021_100734
crossref_primary_10_1016_j_humpath_2021_05_006
crossref_primary_10_1002_gcc_22819
crossref_primary_10_1055_s_0041_1732823
crossref_primary_10_1007_s11523_018_0590_1
crossref_primary_10_1007_s40272_019_00369_z
crossref_primary_10_1200_EDBK_280729
crossref_primary_10_1097_PAS_0000000000001880
crossref_primary_10_1186_s40792_024_01971_1
crossref_primary_10_1007_s40263_024_01121_z
crossref_primary_10_1158_0008_5472_CAN_21_1191
crossref_primary_10_1080_07391102_2024_2302944
crossref_primary_10_3390_diagnostics11040690
crossref_primary_10_1007_s00381_022_05662_w
crossref_primary_10_1016_j_cpccr_2022_100158
crossref_primary_10_1089_thy_2019_0792
crossref_primary_10_3390_ijms19123784
crossref_primary_10_1007_s00104_023_02002_9
crossref_primary_10_1136_jclinpath_2018_205679
crossref_primary_10_3390_genes10090723
crossref_primary_10_3390_biomedicines11092538
crossref_primary_10_1111_neup_12513
crossref_primary_10_1097_PAS_0000000000001194
crossref_primary_10_1038_s41586_023_06678_1
crossref_primary_10_3390_cancers14092160
crossref_primary_10_1097_PAI_0000000000000933
crossref_primary_10_1093_annonc_mdy539
crossref_primary_10_1016_j_jmoldx_2019_05_006
crossref_primary_10_1097_MPH_0000000000001983
crossref_primary_10_1177_10935266221114017
crossref_primary_10_1158_2159_8290_CD_19_1446
crossref_primary_10_3390_pharmaceutics14122834
crossref_primary_10_1016_j_critrevonc_2021_103564
crossref_primary_10_1200_JCO_24_01854
crossref_primary_10_1016_j_clp_2020_11_007
crossref_primary_10_4000_12swg
crossref_primary_10_1097_PAS_0000000000001982
crossref_primary_10_1016_j_pathol_2021_05_100
crossref_primary_10_1007_s12672_025_03506_y
crossref_primary_10_1038_s41379_020_0574_4
crossref_primary_10_3390_cancers14030712
crossref_primary_10_1159_000519767
crossref_primary_10_1007_s00428_019_02682_x
crossref_primary_10_14348_molcells_2020_0212
crossref_primary_10_2217_fon_2023_0114
crossref_primary_10_1002_cpdd_638
crossref_primary_10_3389_fonc_2023_1235794
crossref_primary_10_3390_ph14070632
crossref_primary_10_1007_s00381_024_06639_7
crossref_primary_10_1002_pbc_30600
crossref_primary_10_1634_theoncologist_2019_0942
crossref_primary_10_1111_cas_15139
crossref_primary_10_3389_fonc_2021_740676
crossref_primary_10_1016_j_critrevonc_2020_103011
crossref_primary_10_1002_gcc_23227
crossref_primary_10_1016_j_apsb_2023_11_010
crossref_primary_10_1007_s11154_023_09840_2
crossref_primary_10_1016_j_det_2021_12_007
crossref_primary_10_3390_cancers13112607
crossref_primary_10_1016_j_gde_2019_02_004
crossref_primary_10_3389_fonc_2022_1099280
crossref_primary_10_1097_MD_0000000000041835
crossref_primary_10_1097_WCO_0000000000000991
crossref_primary_10_1007_s40265_018_1044_x
crossref_primary_10_1002_bmc_4953
crossref_primary_10_1186_s13046_023_02920_w
crossref_primary_10_1097_PAS_0000000000001297
crossref_primary_10_1016_j_stem_2024_08_010
crossref_primary_10_1146_annurev_cancerbio_060921_021828
crossref_primary_10_1002_pbc_28639
crossref_primary_10_1038_s41416_020_0770_5
crossref_primary_10_3390_ijms222112089
crossref_primary_10_1016_j_ejmech_2023_115618
crossref_primary_10_1016_j_jchromb_2018_10_023
crossref_primary_10_1093_annonc_mdz204
crossref_primary_10_1016_j_cancergen_2021_11_006
crossref_primary_10_1097_CCO_0000000000000727
crossref_primary_10_1186_s13569_020_00136_6
crossref_primary_10_1186_s43159_023_00241_3
crossref_primary_10_1016_j_cancergen_2022_01_004
crossref_primary_10_1055_a_1580_7327
crossref_primary_10_1080_17460441_2018_1479740
crossref_primary_10_1097_MOP_0000000000000850
crossref_primary_10_1097_CCO_0000000000001148
crossref_primary_10_1111_his_14432
crossref_primary_10_1002_cam4_4561
crossref_primary_10_1188_21_CJON_181_187
crossref_primary_10_3390_cancers17030442
crossref_primary_10_1053_j_seminoncol_2020_02_009
crossref_primary_10_1182_bloodadvances_2019000700
crossref_primary_10_1016_j_tet_2025_134833
crossref_primary_10_3389_fonc_2019_00913
crossref_primary_10_3389_fonc_2020_00489
crossref_primary_10_1097_DAD_0000000000001734
crossref_primary_10_1177_1066896920905888
crossref_primary_10_1002_pbc_28628
crossref_primary_10_1016_j_gore_2021_100845
crossref_primary_10_1016_j_prp_2024_155406
crossref_primary_10_1080_08880018_2021_1889730
crossref_primary_10_3389_fonc_2023_1176790
crossref_primary_10_3390_cells13121071
crossref_primary_10_1002_adsc_202001043
crossref_primary_10_1002_path_5457
crossref_primary_10_1016_j_prp_2019_152572
crossref_primary_10_1016_S1470_2045_19_30304_3
crossref_primary_10_1158_2159_8290_CD_20_0779
crossref_primary_10_3389_fonc_2023_1206833
crossref_primary_10_1007_s12029_024_01149_w
crossref_primary_10_1097_PAS_0000000000001718
crossref_primary_10_1080_14737140_2019_1682554
crossref_primary_10_1111_his_14443
crossref_primary_10_3390_ijms23073849
crossref_primary_10_1093_pch_pxac123
crossref_primary_10_1007_s00112_021_01346_y
crossref_primary_10_1002_pbc_28871
crossref_primary_10_1158_0008_5472_CAN_20_1655
crossref_primary_10_1212_CON_0000000000000955
crossref_primary_10_1097_MPH_0000000000002358
crossref_primary_10_1002_gcc_22846
crossref_primary_10_1038_s41568_019_0169_x
crossref_primary_10_1111_cen_14882
crossref_primary_10_1080_14737140_2019_1538796
crossref_primary_10_1002_cjp2_208
crossref_primary_10_1002_gcc_23132
crossref_primary_10_1002_pbc_30379
crossref_primary_10_1097_HS9_0000000000000229
crossref_primary_10_1002_pbc_31596
crossref_primary_10_1002_pbc_29278
crossref_primary_10_1038_s41392_022_01168_8
crossref_primary_10_3390_cells9040830
crossref_primary_10_1186_s40478_020_00980_z
crossref_primary_10_1002_pbc_28741
crossref_primary_10_3390_diagnostics12020372
crossref_primary_10_3389_fcell_2021_674219
crossref_primary_10_1007_s00256_021_03836_2
crossref_primary_10_1002_pbc_28868
crossref_primary_10_1016_j_critrevonc_2023_103957
crossref_primary_10_1146_annurev_cancerbio_030518_055710
crossref_primary_10_1053_j_seminoncol_2020_02_007
crossref_primary_10_3390_cells11193180
crossref_primary_10_1002_cam4_4356
crossref_primary_10_1038_s41568_021_00418_1
crossref_primary_10_1002_gcc_22853
crossref_primary_10_1097_MPH_0000000000002485
crossref_primary_10_1158_1078_0432_CCR_19_3165
crossref_primary_10_3389_fonc_2021_669197
crossref_primary_10_3389_fphar_2024_1329409
crossref_primary_10_1007_s00428_023_03709_0
crossref_primary_10_1038_s41598_021_95612_4
crossref_primary_10_3390_cancers12010147
crossref_primary_10_1002_pbc_29022
crossref_primary_10_1016_j_cytogfr_2022_08_003
crossref_primary_10_1038_s41568_020_0288_4
crossref_primary_10_3390_cancers16071355
crossref_primary_10_3390_ijms25042366
crossref_primary_10_3390_cancers15051418
crossref_primary_10_1080_14656566_2022_2030704
crossref_primary_10_1016_j_cancergen_2022_02_009
crossref_primary_10_1039_D5OB01049G
crossref_primary_10_1016_j_labinv_2024_102161
crossref_primary_10_2147_CMAR_S368381
crossref_primary_10_1038_s41379_018_0118_3
crossref_primary_10_1080_14737159_2020_1702521
crossref_primary_10_3390_ijms22041831
crossref_primary_10_1016_S1470_2045_19_30691_6
crossref_primary_10_1038_s41379_019_0329_2
crossref_primary_10_3390_ijms25073707
crossref_primary_10_3389_fonc_2021_785855
crossref_primary_10_1038_s41698_022_00324_1
crossref_primary_10_1038_s41598_025_91640_6
crossref_primary_10_1007_s11060_019_03377_8
crossref_primary_10_1111_his_13666
crossref_primary_10_3389_fonc_2025_1588950
crossref_primary_10_1016_j_jos_2021_11_023
crossref_primary_10_1016_j_cancergen_2021_10_007
crossref_primary_10_1016_j_patol_2021_05_003
crossref_primary_10_24953_turkjpediatr_2025_4557
crossref_primary_10_1007_s10147_024_02522_2
crossref_primary_10_3390_cancers15010179
crossref_primary_10_1016_j_ejmech_2021_113627
crossref_primary_10_1093_jjco_hyaf015
crossref_primary_10_1158_1078_0432_CCR_18_0672
crossref_primary_10_1002_pbc_28825
crossref_primary_10_1007_s10014_020_00371_1
crossref_primary_10_1038_s41698_025_00928_3
crossref_primary_10_3390_cancers13194841
crossref_primary_10_1007_s10555_025_10286_y
crossref_primary_10_1002_gcc_22671
crossref_primary_10_1016_j_dld_2022_05_013
crossref_primary_10_1016_j_ejca_2019_02_011
crossref_primary_10_3390_ijms26073123
crossref_primary_10_1007_s11523_022_00887_w
crossref_primary_10_1038_s41698_020_00130_7
crossref_primary_10_1038_s41585_024_00993_6
crossref_primary_10_1038_s41392_020_0205_z
crossref_primary_10_1177_10935266211012186
crossref_primary_10_1016_j_epsc_2022_102465
crossref_primary_10_1016_j_ejca_2025_115308
crossref_primary_10_1016_j_jpedsurg_2019_10_051
crossref_primary_10_1177_1753466620938553
crossref_primary_10_1186_s40478_020_00902_z
crossref_primary_10_24287_1726_1708_2022_21_1_110_120
crossref_primary_10_1016_j_annonc_2020_03_299
crossref_primary_10_1016_j_ctrv_2024_102747
crossref_primary_10_1016_j_path_2022_09_007
crossref_primary_10_1002_cam4_4307
crossref_primary_10_3390_cancers13174324
crossref_primary_10_24287_1726_1708_2019_18_4_109_117
crossref_primary_10_1016_S2352_4642_21_00159_0
crossref_primary_10_1002_cncy_22353
crossref_primary_10_1007_s11154_023_09833_1
crossref_primary_10_1093_pch_pxad044
crossref_primary_10_3390_diagnostics10090648
crossref_primary_10_1177_00099228211021277
crossref_primary_10_1007_s00292_020_00864_y
crossref_primary_10_1016_j_ejcped_2023_100024
crossref_primary_10_1002_cnr2_1616
crossref_primary_10_1038_s41416_020_01103_0
crossref_primary_10_1038_s41571_018_0113_0
crossref_primary_10_1002_pbc_28028
crossref_primary_10_1080_03007995_2020_1847057
crossref_primary_10_1158_1078_0432_CCR_21_0465
crossref_primary_10_1002_pbc_28700
crossref_primary_10_1007_s00401_023_02558_0
crossref_primary_10_1093_bjr_tqae016
crossref_primary_10_3389_fphar_2019_00698
crossref_primary_10_1007_s12094_020_02399_3
crossref_primary_10_1016_j_jmoldx_2019_03_008
crossref_primary_10_1124_jpet_119_264499
crossref_primary_10_1007_s12519_023_00700_2
crossref_primary_10_1016_j_esmorw_2024_100057
crossref_primary_10_1016_j_annonc_2020_06_010
crossref_primary_10_1126_science_aaw4153
crossref_primary_10_2217_fon_2019_0534
crossref_primary_10_1016_j_ejmech_2023_115291
crossref_primary_10_1016_j_drup_2023_101013
crossref_primary_10_1002_cncr_33750
crossref_primary_10_1002_1878_0261_13678
crossref_primary_10_18027_2224_5057_2023_13_3s1_7_17
crossref_primary_10_1080_14737140_2019_1686979
Cites_doi 10.1200/JCO.2007.12.7712
10.1200/JCO.1993.11.8.1466
10.1038/ng.2938
10.1136/esmoopen-2015-000023
10.1002/pbc.26433
10.1200/JCO.2009.21.9972
10.1002/cncr.29887
10.1016/S0304-3835(01)00530-4
10.1016/j.canlet.2015.05.013
10.1309/3H24-E7T7-V37G-AKKQ
10.1016/j.ejca.2015.12.028
10.1002/pbc.26026
10.1038/ncomms5846
10.1038/319743a0
10.1016/j.ejca.2008.10.026
10.1097/00005650-199902000-00003
10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2
10.1002/ijc.29708
10.1097/00006416-198701000-00003
10.1016/j.jpeds.2016.11.040
10.1093/annonc/mdw042
10.1158/2159-8290.CD-15-0443
10.1097/00000478-200007000-00005
10.1016/j.pathol.2015.11.007
10.1056/NEJMoa1714448
10.1158/2159-8290.CD-17-0507
10.1038/sj.bjc.6604826
10.1007/s11136-010-9730-5
10.1200/JCO.2009.26.3541
10.1016/j.pcl.2012.07.003
ContentType Journal Article
Copyright 2018 Elsevier Ltd
Copyright © 2018 Elsevier Ltd. All rights reserved.
Copyright Elsevier Limited May 2018
Copyright_xml – notice: 2018 Elsevier Ltd
– notice: Copyright © 2018 Elsevier Ltd. All rights reserved.
– notice: Copyright Elsevier Limited May 2018
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TO
7X7
7XB
88E
8AO
8C1
8C2
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1016/S1470-2045(18)30119-0
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (subscription)
Lancet Titles
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
Lancet Titles
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Oncogenes and Growth Factors Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7RV
  name: Nursing & Allied Health Database
  url: https://search.proquest.com/nahs
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1474-5488
EndPage 714
ExternalDocumentID 29606586
10_1016_S1470_2045_18_30119_0
S1470204518301190
Genre Multicenter Study
Clinical Trial, Phase II
Clinical Trial, Phase I
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation Loxo Oncology Inc.
GrantInformation_xml – fundername: NCATS NIH HHS
  grantid: UL1 TR001881
GroupedDBID ---
--K
--M
-RU
.1-
.55
.FO
0R~
123
1B1
1P~
1~5
29L
4.4
457
4CK
4G.
53G
5VS
6PF
7-5
71M
7RV
7X7
88E
8AO
8C1
8C2
8FI
8FJ
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAMRU
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABMAC
ABMZM
ABUWG
ABWVN
ACGFS
ACIEU
ACLOT
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFKRA
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGQPQ
AHMBA
AIGII
AIIUN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BENPR
BKEYQ
BKOJK
BNPGV
BPHCQ
BVXVI
CCPQU
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
HMCUK
HVGLF
HZ~
IHE
J1W
KOM
M1P
M41
MO0
N9A
NAPCQ
O-L
O9-
OC~
OO-
OZT
P-8
P-9
P2P
PCD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
R2-
ROL
RPZ
SDG
SEL
SES
SPCBC
SSH
SSZ
T5K
TLN
UKHRP
UV1
WOW
X7M
XBR
Z5R
~HD
3V.
AACTN
ABLVK
ABYKQ
AFKWA
AHPSJ
AJBFU
AJOXV
AMFUW
RIG
SDF
ZA5
9DU
AAYXX
AFFHD
CITATION
AFCTW
AGCQF
AGRNS
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c494t-50a85bb3eae59e99ceb2f2a89b64f8cb443b51fd7ca7b84cbe9bf93774d28bf93
IEDL.DBID 8C1
ISICitedReferencesCount 317
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000431003000051&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1470-2045
1474-5488
IngestDate Mon Sep 29 04:18:41 EDT 2025
Tue Oct 07 05:32:11 EDT 2025
Mon Jul 21 05:58:24 EDT 2025
Sat Nov 29 07:06:27 EST 2025
Tue Nov 18 22:27:34 EST 2025
Fri Feb 23 02:31:14 EST 2024
Tue Oct 14 19:35:42 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License Copyright © 2018 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c494t-50a85bb3eae59e99ceb2f2a89b64f8cb443b51fd7ca7b84cbe9bf93774d28bf93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/5949072
PMID 29606586
PQID 2030729687
PQPubID 46089
PageCount 10
ParticipantIDs proquest_miscellaneous_2020891543
proquest_journals_2030729687
pubmed_primary_29606586
crossref_primary_10_1016_S1470_2045_18_30119_0
crossref_citationtrail_10_1016_S1470_2045_18_30119_0
elsevier_sciencedirect_doi_10_1016_S1470_2045_18_30119_0
elsevier_clinicalkey_doi_10_1016_S1470_2045_18_30119_0
PublicationCentury 2000
PublicationDate May 2018
2018-05-00
20180501
PublicationDateYYYYMMDD 2018-05-01
PublicationDate_xml – month: 05
  year: 2018
  text: May 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle The lancet oncology
PublicationTitleAlternate Lancet Oncol
PublicationYear 2018
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
References Varni, Limbers, Neighbors (bib27) 2011; 20
Wu, Diaz, Paugh (bib8) 2014; 46
Orbach, Rey, Cecchetto (bib15) 2010; 28
Amatu, Sartore-Bianchi, Siena (bib3) 2016; 1
Mitchell, Lu, Myers (bib28) 2016; 138
Eisenhauer, Therasse, Bogaerts (bib18) 2009; 45
Brodeur, Pritchard, Berthold (bib20) 1993; 11
Drilon, Laetsch, Kummar (bib17) 2018; 378
El Demellawy, Cundiff, Nasr (bib12) 2016; 48
Nagasubramanian, Wei, Gordon, Rastatter, Cox, Pappo (bib23) 2016; 63
Prasad, Vyas, Horne (bib13) 2016; 122
Drilon, Li, Dogan (bib31) 2016; 27
Wen, Macdonald, Reardon (bib19) 2010; 28
Drilon, Nagasubramanian, Blake (bib30) 2017; 7
Orsatti, Beltrame, Crimi, Frigo, Bisogno, Stramare (bib33) 2017; 182
Rubin, Segal (bib2) 2003; 115
Knezevich, Garnett, Pysher, Beckwith, Grundy, Sorensen (bib11) 1998; 58
Sheng, Hisaoka, Okamoto (bib9) 2001; 115
Bourgeois, Knezevich, Mathers, Sorensen (bib10) 2000; 24
Funk, Brown, Abdel-Rahman (bib32) 2012; 59
Varni, Burwinkle, Seid, Skarr (bib26) 2003; 3
Creancier, Vandenberghe, Gomes (bib4) 2015; 365
Skolnik, Barrett, Jayaraman, Patel, Adamson (bib21) 2008; 26
Martin-Zanca, Hughes, Barbacid (bib5) 1986; 319
(bib22) 1987
Orbach, Brennan, De Paoli (bib14) 2016; 57
Nakagawara (bib1) 2001; 169
Baker, Wong (bib24) 1987; 6
Varni, Seid, Rode (bib25) 1999; 37
Sung, Klaassen, Dix (bib29) 2009; 100
Stransky, Cerami, Schalm, Kim, Lengauer (bib6) 2014; 5
Pavlick, Schrock, Malicki (bib7) 2017; 64
Doebele, Davis, Vaishnavi (bib16) 2015; 5
(10.1016/S1470-2045(18)30119-0_bib22) 1987
Creancier (10.1016/S1470-2045(18)30119-0_bib4) 2015; 365
Drilon (10.1016/S1470-2045(18)30119-0_bib17) 2018; 378
Amatu (10.1016/S1470-2045(18)30119-0_bib3) 2016; 1
Wen (10.1016/S1470-2045(18)30119-0_bib19) 2010; 28
Eisenhauer (10.1016/S1470-2045(18)30119-0_bib18) 2009; 45
Rubin (10.1016/S1470-2045(18)30119-0_bib2) 2003; 115
Drilon (10.1016/S1470-2045(18)30119-0_bib30) 2017; 7
Sheng (10.1016/S1470-2045(18)30119-0_bib9) 2001; 115
Orbach (10.1016/S1470-2045(18)30119-0_bib14) 2016; 57
Prasad (10.1016/S1470-2045(18)30119-0_bib13) 2016; 122
Drilon (10.1016/S1470-2045(18)30119-0_bib31) 2016; 27
Brodeur (10.1016/S1470-2045(18)30119-0_bib20) 1993; 11
Sung (10.1016/S1470-2045(18)30119-0_bib29) 2009; 100
Varni (10.1016/S1470-2045(18)30119-0_bib26) 2003; 3
Funk (10.1016/S1470-2045(18)30119-0_bib32) 2012; 59
El Demellawy (10.1016/S1470-2045(18)30119-0_bib12) 2016; 48
Nakagawara (10.1016/S1470-2045(18)30119-0_bib1) 2001; 169
Varni (10.1016/S1470-2045(18)30119-0_bib27) 2011; 20
Wu (10.1016/S1470-2045(18)30119-0_bib8) 2014; 46
Orbach (10.1016/S1470-2045(18)30119-0_bib15) 2010; 28
Varni (10.1016/S1470-2045(18)30119-0_bib25) 1999; 37
Doebele (10.1016/S1470-2045(18)30119-0_bib16) 2015; 5
Skolnik (10.1016/S1470-2045(18)30119-0_bib21) 2008; 26
Martin-Zanca (10.1016/S1470-2045(18)30119-0_bib5) 1986; 319
Orsatti (10.1016/S1470-2045(18)30119-0_bib33) 2017; 182
Mitchell (10.1016/S1470-2045(18)30119-0_bib28) 2016; 138
Bourgeois (10.1016/S1470-2045(18)30119-0_bib10) 2000; 24
Baker (10.1016/S1470-2045(18)30119-0_bib24) 1987; 6
Stransky (10.1016/S1470-2045(18)30119-0_bib6) 2014; 5
Nagasubramanian (10.1016/S1470-2045(18)30119-0_bib23) 2016; 63
Pavlick (10.1016/S1470-2045(18)30119-0_bib7) 2017; 64
Knezevich (10.1016/S1470-2045(18)30119-0_bib11) 1998; 58
29606584 - Lancet Oncol. 2018 May;19(5):594-595
29726388 - Lancet Oncol. 2018 May;19(5):e229
References_xml – volume: 45
  start-page: 228
  year: 2009
  end-page: 247
  ident: bib18
  article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  publication-title: Eur J Cancer
– volume: 37
  start-page: 126
  year: 1999
  end-page: 139
  ident: bib25
  article-title: PedsQL Measurement Model for the Pediatric Quality of Life Inventory
  publication-title: Med Care
– volume: 182
  start-page: 327
  year: 2017
  ident: bib33
  article-title: Radiologic response assessment in pediatric soft tissue sarcoma: computed-assisted volume evaluation
  publication-title: J Pediatr
– volume: 28
  start-page: 1963
  year: 2010
  end-page: 1972
  ident: bib19
  article-title: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
  publication-title: J Clin Oncol
– volume: 6
  start-page: 11
  year: 1987
  end-page: 21
  ident: bib24
  article-title: QUEST: a process of pain assessment in children
  publication-title: Orthopaedic Nursing
– volume: 319
  start-page: 743
  year: 1986
  end-page: 748
  ident: bib5
  article-title: A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
  publication-title: Nature
– volume: 5
  start-page: 4846
  year: 2014
  ident: bib6
  article-title: The landscape of kinase fusions in cancer
  publication-title: Nat Commun
– volume: 24
  start-page: 937
  year: 2000
  end-page: 946
  ident: bib10
  article-title: Molecular detection of the
  publication-title: Am J Surg Pathol
– year: 1987
  ident: bib22
  publication-title: TNM classification of malignant tumors
– volume: 59
  start-page: 1001
  year: 2012
  end-page: 1016
  ident: bib32
  article-title: Pediatric pharmacokinetics: human development and drug disposition
  publication-title: Pediatr Clin North Am
– volume: 64
  start-page: e26433
  year: 2017
  ident: bib7
  article-title: Identification of NTRK fusions in pediatric mesenchymal tumors
  publication-title: Pediatr Blood Cancer
– volume: 1
  start-page: e000023
  year: 2016
  ident: bib3
  article-title: NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
  publication-title: ESMO Open
– volume: 122
  start-page: 1097
  year: 2016
  end-page: 1107
  ident: bib13
  article-title: NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
  publication-title: Cancer
– volume: 5
  start-page: 1049
  year: 2015
  end-page: 1057
  ident: bib16
  article-title: An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101
  publication-title: Cancer Discov
– volume: 365
  start-page: 107
  year: 2015
  end-page: 111
  ident: bib4
  article-title: Chromosomal rearrangements involving the
  publication-title: Cancer Lett
– volume: 63
  start-page: 1468
  year: 2016
  end-page: 1470
  ident: bib23
  article-title: Infantile fibrosarcoma with
  publication-title: Pediatr Blood Cancer
– volume: 28
  start-page: 318
  year: 2010
  end-page: 323
  ident: bib15
  article-title: Infantile fibrosarcoma: management based on the European experience
  publication-title: J Clin Oncol
– volume: 7
  start-page: 963
  year: 2017
  end-page: 972
  ident: bib30
  article-title: A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors
  publication-title: Cancer Discov
– volume: 11
  start-page: 1466
  year: 1993
  end-page: 1477
  ident: bib20
  article-title: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
  publication-title: J Clin Oncol
– volume: 115
  start-page: 1
  year: 2003
  end-page: 18
  ident: bib2
  article-title: Growth, survival and migration: the Trk to cancer
  publication-title: Cancer Treat Res
– volume: 58
  start-page: 5046
  year: 1998
  end-page: 5048
  ident: bib11
  article-title: gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma
  publication-title: Cancer Res
– volume: 100
  start-page: 82
  year: 2009
  end-page: 88
  ident: bib29
  article-title: Identification of paediatric cancer patients with poor quality of life
  publication-title: Br J Cancer
– volume: 115
  start-page: 348
  year: 2001
  end-page: 355
  ident: bib9
  article-title: Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues
  publication-title: Am J Clin Pathol
– volume: 3
  start-page: 329
  year: 2003
  end-page: 341
  ident: bib26
  article-title: The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity
  publication-title: Ambul Pediatr
– volume: 378
  start-page: 731
  year: 2018
  end-page: 739
  ident: bib17
  article-title: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
  publication-title: N Engl J Med
– volume: 46
  start-page: 444
  year: 2014
  end-page: 450
  ident: bib8
  article-title: The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
  publication-title: Nat Genet
– volume: 57
  start-page: 1
  year: 2016
  end-page: 9
  ident: bib14
  article-title: Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience
  publication-title: Eur J Cancer
– volume: 20
  start-page: 45
  year: 2011
  end-page: 55
  ident: bib27
  article-title: The PedsQL Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants
  publication-title: Qual Life Res
– volume: 27
  start-page: 920
  year: 2016
  end-page: 926
  ident: bib31
  article-title: What hides behind the MASC: clinical response and acquired resistance to entrectinib after
  publication-title: Ann Oncol
– volume: 169
  start-page: 107
  year: 2001
  end-page: 114
  ident: bib1
  article-title: Trk receptor tyrosine kinases: a bridge between cancer and neural development
  publication-title: Cancer Lett
– volume: 138
  start-page: 332
  year: 2016
  end-page: 339
  ident: bib28
  article-title: Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331
  publication-title: Int J Cancer
– volume: 48
  start-page: 47
  year: 2016
  end-page: 50
  ident: bib12
  article-title: Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and
  publication-title: Pathology
– volume: 26
  start-page: 190
  year: 2008
  end-page: 195
  ident: bib21
  article-title: Shortening the timeline of pediatric phase I trials: the rolling six design
  publication-title: J Clin Oncol
– volume: 26
  start-page: 190
  year: 2008
  ident: 10.1016/S1470-2045(18)30119-0_bib21
  article-title: Shortening the timeline of pediatric phase I trials: the rolling six design
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.12.7712
– volume: 11
  start-page: 1466
  year: 1993
  ident: 10.1016/S1470-2045(18)30119-0_bib20
  article-title: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1993.11.8.1466
– volume: 46
  start-page: 444
  year: 2014
  ident: 10.1016/S1470-2045(18)30119-0_bib8
  article-title: The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
  publication-title: Nat Genet
  doi: 10.1038/ng.2938
– year: 1987
  ident: 10.1016/S1470-2045(18)30119-0_bib22
– volume: 1
  start-page: e000023
  year: 2016
  ident: 10.1016/S1470-2045(18)30119-0_bib3
  article-title: NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2015-000023
– volume: 64
  start-page: e26433
  year: 2017
  ident: 10.1016/S1470-2045(18)30119-0_bib7
  article-title: Identification of NTRK fusions in pediatric mesenchymal tumors
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26433
– volume: 28
  start-page: 318
  year: 2010
  ident: 10.1016/S1470-2045(18)30119-0_bib15
  article-title: Infantile fibrosarcoma: management based on the European experience
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.21.9972
– volume: 58
  start-page: 5046
  year: 1998
  ident: 10.1016/S1470-2045(18)30119-0_bib11
  article-title: ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma
  publication-title: Cancer Res
– volume: 122
  start-page: 1097
  year: 2016
  ident: 10.1016/S1470-2045(18)30119-0_bib13
  article-title: NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
  publication-title: Cancer
  doi: 10.1002/cncr.29887
– volume: 169
  start-page: 107
  year: 2001
  ident: 10.1016/S1470-2045(18)30119-0_bib1
  article-title: Trk receptor tyrosine kinases: a bridge between cancer and neural development
  publication-title: Cancer Lett
  doi: 10.1016/S0304-3835(01)00530-4
– volume: 365
  start-page: 107
  year: 2015
  ident: 10.1016/S1470-2045(18)30119-0_bib4
  article-title: Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.05.013
– volume: 115
  start-page: 348
  year: 2001
  ident: 10.1016/S1470-2045(18)30119-0_bib9
  article-title: Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues
  publication-title: Am J Clin Pathol
  doi: 10.1309/3H24-E7T7-V37G-AKKQ
– volume: 57
  start-page: 1
  year: 2016
  ident: 10.1016/S1470-2045(18)30119-0_bib14
  article-title: Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.12.028
– volume: 63
  start-page: 1468
  year: 2016
  ident: 10.1016/S1470-2045(18)30119-0_bib23
  article-title: Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26026
– volume: 5
  start-page: 4846
  year: 2014
  ident: 10.1016/S1470-2045(18)30119-0_bib6
  article-title: The landscape of kinase fusions in cancer
  publication-title: Nat Commun
  doi: 10.1038/ncomms5846
– volume: 319
  start-page: 743
  year: 1986
  ident: 10.1016/S1470-2045(18)30119-0_bib5
  article-title: A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
  publication-title: Nature
  doi: 10.1038/319743a0
– volume: 45
  start-page: 228
  year: 2009
  ident: 10.1016/S1470-2045(18)30119-0_bib18
  article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.10.026
– volume: 37
  start-page: 126
  year: 1999
  ident: 10.1016/S1470-2045(18)30119-0_bib25
  article-title: PedsQL Measurement Model for the Pediatric Quality of Life Inventory
  publication-title: Med Care
  doi: 10.1097/00005650-199902000-00003
– volume: 3
  start-page: 329
  year: 2003
  ident: 10.1016/S1470-2045(18)30119-0_bib26
  article-title: The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity
  publication-title: Ambul Pediatr
  doi: 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2
– volume: 138
  start-page: 332
  year: 2016
  ident: 10.1016/S1470-2045(18)30119-0_bib28
  article-title: Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29708
– volume: 115
  start-page: 1
  year: 2003
  ident: 10.1016/S1470-2045(18)30119-0_bib2
  article-title: Growth, survival and migration: the Trk to cancer
  publication-title: Cancer Treat Res
– volume: 6
  start-page: 11
  year: 1987
  ident: 10.1016/S1470-2045(18)30119-0_bib24
  article-title: QUEST: a process of pain assessment in children
  publication-title: Orthopaedic Nursing
  doi: 10.1097/00006416-198701000-00003
– volume: 182
  start-page: 327
  year: 2017
  ident: 10.1016/S1470-2045(18)30119-0_bib33
  article-title: Radiologic response assessment in pediatric soft tissue sarcoma: computed-assisted volume evaluation
  publication-title: J Pediatr
  doi: 10.1016/j.jpeds.2016.11.040
– volume: 27
  start-page: 920
  year: 2016
  ident: 10.1016/S1470-2045(18)30119-0_bib31
  article-title: What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw042
– volume: 5
  start-page: 1049
  year: 2015
  ident: 10.1016/S1470-2045(18)30119-0_bib16
  article-title: An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-15-0443
– volume: 24
  start-page: 937
  year: 2000
  ident: 10.1016/S1470-2045(18)30119-0_bib10
  article-title: Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-200007000-00005
– volume: 48
  start-page: 47
  year: 2016
  ident: 10.1016/S1470-2045(18)30119-0_bib12
  article-title: Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement
  publication-title: Pathology
  doi: 10.1016/j.pathol.2015.11.007
– volume: 378
  start-page: 731
  year: 2018
  ident: 10.1016/S1470-2045(18)30119-0_bib17
  article-title: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1714448
– volume: 7
  start-page: 963
  year: 2017
  ident: 10.1016/S1470-2045(18)30119-0_bib30
  article-title: A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-17-0507
– volume: 100
  start-page: 82
  year: 2009
  ident: 10.1016/S1470-2045(18)30119-0_bib29
  article-title: Identification of paediatric cancer patients with poor quality of life
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604826
– volume: 20
  start-page: 45
  year: 2011
  ident: 10.1016/S1470-2045(18)30119-0_bib27
  article-title: The PedsQL Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants
  publication-title: Qual Life Res
  doi: 10.1007/s11136-010-9730-5
– volume: 28
  start-page: 1963
  year: 2010
  ident: 10.1016/S1470-2045(18)30119-0_bib19
  article-title: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.26.3541
– volume: 59
  start-page: 1001
  year: 2012
  ident: 10.1016/S1470-2045(18)30119-0_bib32
  article-title: Pediatric pharmacokinetics: human development and drug disposition
  publication-title: Pediatr Clin North Am
  doi: 10.1016/j.pcl.2012.07.003
– reference: 29726388 - Lancet Oncol. 2018 May;19(5):e229
– reference: 29606584 - Lancet Oncol. 2018 May;19(5):594-595
SSID ssj0017105
Score 2.6843777
Snippet Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective...
Summary Background Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib,...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 705
SubjectTerms Administration, Oral
Adolescent
Adolescents
Age
Age Factors
Alanine
Alanine transaminase
Anthracycline
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Aspartate aminotransferase
Biomarkers, Tumor - antagonists & inhibitors
Biomarkers, Tumor - genetics
Cancer therapies
Central nervous system
Chemotherapy
Child
Child, Preschool
Children
Clinical trials
Discoidin Domain Receptor 2 - antagonists & inhibitors
Discoidin Domain Receptor 2 - genetics
Drug Administration Schedule
Female
Fibrosarcoma
Gene Fusion
Humans
Infant
Infants
Kinases
Leukopenia
Male
Membrane Glycoproteins - antagonists & inhibitors
Membrane Glycoproteins - genetics
Metastases
Metastasis
Nausea
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - pathology
Neuroblastoma
Neutrophils
Oncology
Papillary thyroid cancer
Patients
Pediatrics
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Pyrazoles - administration & dosage
Pyrazoles - adverse effects
Pyrimidines - administration & dosage
Pyrimidines - adverse effects
Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
Receptor Protein-Tyrosine Kinases - genetics
Receptor, trkA - antagonists & inhibitors
Receptor, trkA - genetics
Receptor, trkB - antagonists & inhibitors
Receptor, trkB - genetics
Safety
Solid tumors
Surgery
Thyroid cancer
Time Factors
Toxicity
Treatment Outcome
Tumors
United States
Vomiting
Young Adult
Title Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1470204518301190
https://dx.doi.org/10.1016/S1470-2045(18)30119-0
https://www.ncbi.nlm.nih.gov/pubmed/29606586
https://www.proquest.com/docview/2030729687
https://www.proquest.com/docview/2020891543
Volume 19
WOSCitedRecordID wos000431003000051&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251009
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 7X7
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Nursing & Allied Health Database
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251009
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 7RV
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251009
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: BENPR
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251009
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 8C1
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoixAX3o-FsjISB5BqmocT21wQVK2QKKtqKWhvlu046kpLdtkk_AZ-NjPOo6dSJC5RlHisRPN5Xh7PEPIqK2JpnfEAXmsZ90nKlDM5E0ZmpkhxVzF0LTkVs5lcLNRZH3Cr-7TKQSYGQV2sHcbIwUlPsch1LsX7zU-GXaNwd7VvobFD9uIk4rgw5dGY4hGLLoUx5iJiWHb98gTP4dfx4etYvkGUKxZdpZuusj2DDjq5-79ff4_c6a1P-qGDy31yw1cPyK0v_f76Q_L71GzXTRCC1dJSMGjpxgzNPCjAdFnQpv0B09T0wmwxIgqqj87O558pINHTssXoW_2Obi5APdKYgjffrpqa4jEWamjIXwwJof6AYucuBij0q4Nh_GFCQ8HbR-TbyfH50SfW92pgjivesCwC5lqbeuMz5ZVy4LGXiZHK5ryUznKe2iwuC-GMsJI765UtwTQSvEgk3j0mu9W68k8JzVxuSuNLlxWSKwc-uothvE2dzUC38gnhA5e06wuZYz-NlR4z1pC5GpmrY6kDc3U0IW9Hsk1XyeM6gnyAgB6OqYJg1aBrriOUI2Fvx3T2yb-Q7g_40b0wqfUleCbk5fgaxADu7ZjKr1sck0RSgT2cTsiTDqPjXybopWYyf_b3yZ-T22ANyi6bc5_sNtvWvyA33a9mWW-nZEfMv-N1IcJVTsNam5K9j8ezs_kfTZ8q7w
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKQZQLe2GggJFAAqmmWZzERkIIFapWMx0hmEq9Gdtx1JGGzJAFxD_g1_AbeS9bT6VceuAWJX5W4nxvs99CyLMo9YWx2gF4jWHcBSGTVscs0SLSaYinik3XkkkynYrjY_lxjfzuc2EwrLKXiY2gTpcW98jBSQ-xyHUskrerbwy7RuHpat9Co4XF2P38AS5b-ebgPfzf50Gw92G2u8-6rgLMcskrFnnwGsaETrtIOikt-JZZoIU0Mc-ENZyHJvKzNLE6MYJb46TJQIknPA0EXsG8l8hlrGSHzp7YHUJK_KQNmfR54jEs836aMbTzebj5whcvkask887ShWfZuo3O27vxv63WTXK9s67pu5YdbpE1l98mVw-7-IE75NdEF8uqEfL53FAw2OlK981KKLDhPKVV_RWmKemJLnDHF1Q7nc4-jSlwmqNZjbuL5Wu6OgH1T31auLJeVCXFNB2qaROf2QS8um2KnckYcJlbbPfjdwLaFPS9S44uZB02yXq-zN19QiMb60y7zEap4NImQlgfxpvQmghsBz4ivEeFsl2hduwXslBDRB6CSSGYlC9UAybljcirgWzVVio5jyDuIaf6NFxQHAp06XmEYiDs7LTW_voX0q0er6oTlqU6BeuIPB0eg5jDsyudu2WNYwJPSLD3wxG51_LE8JUBeuGRiB_8ffInZGN_djhRk4Pp-CG5BpavaCNXt8h6VdTuEbliv1fzsnjccDUlXy6aMf4A9UaG9w
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1ZbxMxELZKQRUv3EeggJFAAqlL9vCubSSEUEtElRBV0Ep9M7bXq0YKm7AHiH_Ab-LXMbNXn0p56QNvUeKxks03l_3NDCHP4jQQxmoH4DXGYy6MPGl14nEtYp1GeKvYTC2Z8flcHB_Lgw3yu6-FQVplbxMbQ52uLJ6RQ5IeYZPrRPBx1tEiDvYmb9ffPJwghTet_TiNFiJT9_MHpG_lm_09-K-fh-Hk_eHuB6-bMOBZJlnlxT58JWMip10snZQW8sws1EKahGXCGsYiEwdZyq3mRjBrnDQZOHTO0lDgK9j3ErnMI0AxVqnvDvSSgLf0yYBx38OW76fVQ-PPw5svAvESNUx6_ll-8ay4t_F_k-v_85O7Qa51UTd916rJTbLh8ltk62PHK7hNfs10saoa458vDIVAnq51P8SEgnouUlrVX2Gbkp7oAk-CweXT-eGnKQUNdDSr8dSxfE3XJxAW0IAWrqyXVUmxfIdq2vA2GyKs26E4scwD7XPLnX79OKRNo9875OhCnsNdspmvcnef0NgmOtMus3EqmLRcCBvAehNZE0NMwUaE9QhRtmvgjnNElmpg6iGwFAJLBUI1wFL-iLwaxNZtB5PzBJIefqovzwWHosDHnicoBsEufmvjsn8R3e6xqzojWqpT4I7I0-FjMH94p6Vzt6pxTegLCXlANCL3Wv0YfmWI2Xkskgd_3_wJ2QJ9ULP9-fQhuQoBsWgJrdtksypq94hcsd-rRVk8bhScki8XrRd_AJ3ij7w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Larotrectinib+for+paediatric+solid+tumours+harbouring+NTRK+gene+fusions%3A+phase+1+results+from+a+multicentre%2C+open-label%2C+phase+1%2F2+study&rft.jtitle=The+lancet+oncology&rft.au=Laetsch%2C+Theodore+W&rft.au=DuBois%2C+Steven+G&rft.au=Mascarenhas%2C+Leo&rft.au=Turpin%2C+Brian&rft.date=2018-05-01&rft.issn=1474-5488&rft.eissn=1474-5488&rft.volume=19&rft.issue=5&rft.spage=705&rft_id=info:doi/10.1016%2FS1470-2045%2818%2930119-0&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-2045&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-2045&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-2045&client=summon